Human herpesvirus 8 (HHV8) is endemic in Africa, although studies of this infection are rare in Congo. We evaluated seroprevalence and HHV-8 diversity among people living with HIV. We included 353 patients receiving highly active antiretroviral therapy. Antibodies against HHV-8 latency-associated nuclear antigen were detected by indirect immunofluorescence. In HHV-8 positive patients, we performed HHV-8 quantification in blood and saliva by real-time PCR and typing by Sanger sequencing of K1 open reading frame. HHV-8 seroprevalence was 19%, being male (odd ratio [OR] = 1.741, [95% Confidence interval {CI}, 0.97–3.07]; p = 0.0581) and having multiple sex partners before HIV diagnosis (OR = 1.682, [CI 95%, 0.97–2.92]; p = 0.0629) tended to be associated with HHV-8 seropositivity. Of the 64 HHV-8 seropositive patients, HHV-8 DNA was detected in 10 (16%) in saliva, 6 (9%) in whole-blood and in 2 (3%) in both whole-blood and saliva. Three out of 6 HHV-8 strains were subtypes A5, 2 subtype B1 and 1 subtype C. HHV-8 seroprevalence was relatively low with more frequent carriage in men, associated with asymptomatic oral excretion and a predominance of subtype A5. These data tend to support the hypothesis of horizontal transmission in people living with HIV in Brazzaville.
Introduction: Breast cancer is a heterogeneous disease with a variety of morphological, molecular, treatment response and clinical outcome characteristics. The objective of this work was to assess the epidemiological, histological, immunohistochemical and molecular subtypes of breast cancer in women in the Republic of Congo. Material and Methods: We carried out a cross-sectional descriptive study which took place from January 1, 2014 to December 31, 2020. The study focused on 150 cases of breast cancer in patients diagnosed at the University Hospital of Brazzaville (CHU-B). The epidemiological, clinical, histological, immunohistochemical and molecular subtypes were the variables studied. Results: The mean age was 48.09 ± 13.87 years with the extremes of 22 years and 80 years. The study of the profession; the most represented in our study was that of the cultivator 20.67%. A predominance of breast cancer localization was observed in the left breast in 47.33%. The frequency of a family history was 7.33% or 11 cases. The most frequently represented histologic type was 62% invasive non-specific type carcinoma (CITNS). The most represented histological grade was Scarff Bloom Richardson grade II (51.33%), followed by grade III 24% and grade I in 12% of cases. Regarding the results of IHC; of the 150 cases, 102 (68%) had positive hormone receptors (HR +). The ORs were positive in 102 cases (68%) while the PRs were positive in 98 cases (65.33%). The Her2 oncogene was over expressed in 38 cases (25.3%). The Ki-67 proliferation index was known for the 150 cases, including 77 (51.33%) less than 15% and 73 (48.67%) greater than or equal to 15%. The distribution of molecular subtypes was 46% luminal A, 22% triple negative, 17% luminal B and 10% Her2 +. Tumors of unknown molecular profile were 5%. The correlation was found between molecular subtype and histological type. This result was statistically significant (p <0.05). For the rest. There was no correlation between age and SBR grade (p> 0.05). The correlation was found between molecular subtype and histological type. This result was statistically significant (p <0.05). For the rest. There was no correlation between age and SBR grade (p> 0.05). The correlation was found between molecular subtype and histological type. This result was statistically significant (p <0.05). For the rest. There was no correlation between age and SBR grade (p> 0.05). Conclusion: It should be noted that the association between histological and immunohistochemical diagnosis can help determine the phenotype of breast cancer, with the aim of guiding treatment and therefore improving response to treatment. Key words: Epidemiology, Histology, Immunohistochemistry, molecular subtypes, breast cancer, Republic of Congo.
Introduction: the Epstein Barr virus is one of the very first oncogenic viruses to be identified as responsible for human malignancies. Its role as an etiological agent of breast cancer remains controversial, however, despite the growing molecular evidence. The aim of this study was detected the presence of EBV DNA in patients with breast cancer in the Republic of Congo. Methods: The study was conducted on 90 samples of formalin fixed and paraffin-embedded tissue blocks (FFPE) from breast cancer tissue. The immunohistochemistry technique was used to test for the expression of the LMP1 antibody and DNA was extracted from all blocks of formalin-fixed and paraffin-embedded breast cancer tissue (FFPE) to detect presence of EBV 1 DNA by real-time polymerase chain reaction (PCR). Results: EBV was detected in 12.33% (12/90) of formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue blocks. All formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue blocks with positive EBV DNA were high tumor grades (II and III). Overall EBV infection with clinicopathological features of breast cancer cases showed no significant difference (P>0.05). However, a statistically significant difference was observed between EBV infection and histological types (P=0.04). Conclusion: Our results provide evidence for the presence of EBV DNA in female breast cancer in Congo Brazzaville. However, this evidence is substantial but inconclusive for the involvement of viruses in the development of breast cancer. Therefore, future investigations will be needed to elucidate the exact role of EBV in breast cancer in women in the Republic of Congo. Key words: EBV, breast cancer, women, Congo Brazzaville.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.